Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Receptor-targeted cancer therapy.

Mark Richter1, Hongtao Zhang

  • 1Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104-6082, USA.

DNA and Cell Biology
|May 5, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prevalence and influencing factors of oral frailty in older adults: a systematic review and meta-analysis.

Frontiers in public health·2024
Same author

Integrated lipidomics and RNA-seq reveal prognostic biomarkers in well-differentiated and dedifferentiated retroperitoneal liposarcoma.

Cancer cell international·2024
Same author

Outcomes of Simultaneous Correction of Adult Hallux Valgus and Flexible Pes Planus Deformities.

Orthopedics·2024
Same author

Lubricating and Dual-Responsive Injectable Hydrogels Formulated From ZIF-8 Facilitate Osteoarthritis Treatment by Remodeling the Microenvironment.

Small (Weinheim an der Bergstrasse, Germany)·2024
Same author

Deep learning model for automated diagnosis of moyamoya disease based on magnetic resonance angiography.

EClinicalMedicine·2024
Same author

Predictive Value of the Systemic Immune-Inflammation Index in the 28-Day Mortality for Patients with Sepsis-Associated Acute Kidney Injury and Construction of a Prediction Model.

Journal of inflammation research·2024

Targeted cancer therapies disrupt oncogenic signaling pathways, offering greater tumor selectivity and fewer side effects than traditional chemotherapy. Research focuses on novel ErbB-directed agents targeting receptor interactions for improved cancer treatment.

Area of Science:

  • Molecular oncology and targeted cancer therapy.
  • Cell surface receptor signaling pathways.

Background:

  • Conventional cancer treatments targeting DNA cause significant toxicity and drug resistance.
  • Targeted strategies offer improved selectivity by disrupting oncogenic signaling molecules.
  • ErbB receptor signaling is implicated in numerous cancers, correlating with poor prognosis.

Purpose of the Study:

  • To review the evolution and promise of ErbB-directed targeted cancer therapies.
  • To highlight advancements in targeting receptor tyrosine kinases and their interactions.

Main Methods:

  • Review of targeted therapy development, including monoclonal antibodies and small molecule inhibitors.
  • Focus on strategies disrupting ErbB receptor signaling pathways (e.g., HER-2/neu, EGFR).

Related Experiment Videos

  • Exploration of novel approaches targeting receptor oligomeric complexes.

    • Main Results:

    • Monoclonal antibodies targeting ErbB receptors (HER-2/neu, EGFR) demonstrated early success in targeted therapy.
    • Small molecule inhibitors targeting the ErbB tyrosine kinase domain are effective.
    • Ongoing development shows promise for novel ErbB-directed entities.

    Conclusions:

    • Targeted therapies, particularly those directed at ErbB receptors, offer improved cancer treatment outcomes.
    • Strategies inhibiting receptor interactions within oligomeric complexes represent a promising future direction.